Caffeine consumption and interaction with ADORA2A, CYP1A2 and NOS1 variants do not influence age at onset of Machado-Joseph disease
Author:
Martins Ana Carolina1, Pinheiro Jordânia dos Santos1, Szinwelski Luciana1, Cidade Eduardo Rockenbach1, Santin Danilo Fernando1, Proença Laura Damke1, Araújo Bruna Almeida1, Saraiva-Pereira Maria Luiza1, Jardim Laura Bannach1
Affiliation:
1. Universidade Federal do Rio Grande do Sul
Abstract
Abstract
Background
The age at onset (AO) of Machado-Joseph disease (SCA3/MJD), a disorder due to an expanded CAG repeat (CAGexp) in ATXN3, is quite variable and the role of environmental factors is still unknown. Caffeine was associated with protective effects against other neurodegenerative diseases, and in transgenic SCA3/MJD mouse models. We aimed to evaluate whether caffeine consumption and the interaction with variants of caffeine signaling/metabolization genes impact the AO of this disease.
Methods
a questionnaire on caffeine consumption was applied to adult patients and unrelated controls living in Rio Grande do Sul, Brazil. AO and CAGexp were previously determined. SNPs rs5751876 (ADORA2A), rs2298383 (ADORA2A), rs762551 (CYP1A2) and rs478597 (NOS1) were genotyped. AO of subgroups were compared, adjusting the CAGexp to 75 repeats (p < 0.05).
Results
171/179 cases and 98/100 controls consumed caffeine. Cases with high and low caffeine consumption (more or less than 314.5 mg of caffeine/day) had mean (SD) AO of 35.05 (11.44) and 35.43 (10.08) years (p = 0.40). The mean (SD) AO of the subgroups produced by the presence or absence of caffeine-enhancing alleles in ADORA2A (T allele at rs5751876 and rs2298383), CYP1A2 (C allele) and NOS1 (C allele) were all similar (p between 0.069 and 0.516).
Discussion
Caffeine consumption was not related to changes in the AO of SCA3/MJD, either alone or in interaction with protective genotypes at ADORA2A, CYP1A2 and NOS1.
Publisher
Research Square Platform LLC
Reference18 articles.
1. 1. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, et al. (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8:221-8. 2. 2. Souza GN, Kersting N, Krum-Santos AC, Santos ASP, Furtado GV, Pacheco D, Gonçalves TA, Saute JA, Schuler-Faccini L, Mattos EP et al (2016) Spinocerebellar ataxia type 3/Machado-Joseph disease: segregation patterns and factors influencing instability of expanded CAG transmissions. Clin Genet 90:134–140. 3. 3. de Mattos E, Musskopf M, Leotti V, Saraiva-Pereira M, Jardim LB. (2019). Genetic risk factors for modulation of age at onset in Machado-Joseph disease/spinocerebellar ataxia type 3: A systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry 90:203–210. 4. 4. Lee YH, Tsai YS, Chang CC, Ho CC, Shih HM, Chen HM, Lai HL, Lee CW, Lee YC, Liao YC, Yang UC, Cheng TH, Chern Y, Soong B (2022) A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis. Mov Disord 37:767–777. 5. 5. Raposo M, Bettencourt C, Melo ARV, Ferreira AF, Alonso I, Silva P, Vasconcelos J, Kay T, Saraiva-Pereira ML, Costa MD, Vilasboas-Campos D, Bettencourt BF, Bruges-Armas J, Houlden H, Heutink P, Jardim LB, Sequeiros J, Maciel P, Lima M. Novel (2022) Machado-Joseph disease-modifying genes and pathways identified by whole-exome sequencing. Neurobiol Dis 162:105578.
|
|